FDA Gives Specialized Cancer-Test Technology a New Regulatory Lane
Published Date: 6/26/2025
Rule
Summary
The FDA is officially classifying a special test that spots chromosome problems in blood cancer patients as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the test is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on June 26, 2025, and could save time and money for companies making these tests.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Class II classification speeds patient access
The FDA officially classified fluorescence in situ hybridization (FISH) tests for chromosomal abnormalities in hematologic malignancies as Class II (special controls) effective June 26, 2025 (classification applicable December 21, 2018). The Agency says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access to innovative tests by reducing regulatory burdens.
New predicate enables easier 510(k) pathway
Because FDA classified this FISH test via the De Novo process, the device can serve as a predicate for future devices of the same type, allowing other sponsors to use the less-burdensome 510(k) premarket notification process rather than a premarket approval (PMA). This change is described as reducing regulatory burdens for future device sponsors.
Manufacturers must meet detailed validation rules
Manufacturers must meet Class II special controls including detailed design verification and validation. Explicit requirements include: analytical sensitivity data with a minimum of 25 specimens from karyotypically normal males; analytical specificity data with a minimum of 5 such specimens; precision/reproducibility with at least 6 clinical specimens (2 negative, 2 near cut-off, 2 positive) tested across 3 sites with 2 operators each over 3–5 non-consecutive days and each specimen run in duplicate for a minimum of 30 replicates; between-reagent lot reproducibility with 3 reagent lots and 3 clinical specimens; and multiple stability studies.
Labeling and lab responsibilities required
Labeling must state: "The test is not intended for use as a stand-alone diagnostic, disease screening, or as a companion diagnostic." The labeling must show performance study results and acceptance criteria, and must include limiting statements that results be interpreted by a qualified pathologist or cytogeneticist. Each laboratory is responsible for establishing its own cut-off values and should test a sufficiently large number of samples to assign a cut-off.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Attenuation
The FDA is officially classifying the cream used to block X-rays as a Class II device with special safety rules. This change makes it easier and safer for patients to get this innovative cream by lowering regulatory hurdles. The new classification is effective June 26, 2025, and helps companies bring these creams to market faster without extra costs.
Next: 2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections
The FDA is officially putting the herpes simplex virus test for brain infections into a safer, easier-to-manage category called Class II. This change means the test will have special rules to keep it safe and effective, helping patients get quicker access to this important tool without unnecessary red tape. The new classification is effective June 26, 2025, and could save time and money for makers and users of the test.